Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.
about
Cutaneous manifestations of hepatitis C in the era of new antiviral agentsHepatitis C in Special Patient Cohorts: New Opportunities in Decompensated Liver Cirrhosis, End-Stage Renal Disease and Transplant MedicineDaclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-AnalysisDrug-Drug Interactions with the NS3/4A Protease Inhibitor SimeprevirHepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis.Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.Management of patients with hepatitis C infection and renal disease.Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation.Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virusSofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients.Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrenceHepatitis C virus infection and kidney transplantation in 2014: what's new?Drug interactions with new hepatitis C oral drugs.Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.Management of Hepatitis C Before and After Liver Transplantation in the Era of Rapidly Evolving Therapeutic Advances.Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review.Drug metabolism and liver disease: a drug-gene-environment interaction.Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.New hepatitis C therapies for special patient populations.Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.Effective epitope identification employing phylogenetic, mutational variability, sequence entropy, and correlated mutation analysis targeting NS5B protein of hepatitis C virus: from bioinformatics to therapeutics.Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.For dentists and doctors: The neglected concepts about the factors influencing the effects of drugs.Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends.
P2860
Q26773669-337A5255-F582-475D-A32D-ADCF3BF651DAQ26801198-946D912F-4ECF-496F-BBD6-6F65FC3FA9EBQ28077287-CB12D640-845E-4BC7-A005-1C02B98CA549Q28084266-D2FC2985-5930-4CA3-89B4-847979056D6BQ30301355-61DF0EDB-1FB0-4C42-ACD7-58626EF6EE6BQ33423299-B7DA3A3B-A196-4430-894A-E5C123D7CC19Q35127041-5CEFE8E3-E8BA-4051-B2EB-44D48FE8B47DQ35270256-E5E519E5-CA38-4B1A-A457-59290FD73C51Q36650834-BF125A16-DA51-4636-9C53-41DA4A0B11D4Q36997118-A66CC59A-C78E-46F0-A495-77B04E88BAA3Q37349067-A5F5B786-87ED-4A38-917E-0FC25B574B8FQ38236820-C1426B51-FF1C-4677-8CA9-A1D66DF5EB0AQ38305640-0A4153AF-659E-4AF6-B309-E3F1A8D167C0Q38503778-C8970EFB-FE36-4315-892B-6BBAA7402143Q38584289-22268339-CEFE-4E62-9F22-FBEA43E2F90FQ38626467-2C3E1ED2-A834-45EF-9DDA-849354B18B3FQ38664453-5FC23351-2AF9-4EED-9C32-F50CC7E0752BQ38874771-E4318CD3-139D-4EF6-A1FB-DC6B3FAF9FE4Q39037269-27DE558B-BBFA-4956-B7FC-73DF716D16EFQ40271866-A4D4FBFA-B7A9-4BF6-8EE5-B7198D9FECA1Q40899794-5CDBE24D-8524-4845-8308-3704C9DDE6A0Q41006072-6F757C17-B855-4462-9AC5-2A15D94C10FFQ41332304-9EA2A79D-1898-4224-9B82-6F6A622AC6C5Q42183060-142B1922-D8F4-4A76-9E75-91CA1F8329ACQ43119385-2156F3A9-9B1C-4098-B1AF-4E9C27B96E91Q47559302-A8303973-81FB-4F52-9F9B-A895F24CFD3A
P2860
Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Drug-drug interactions with or ...... the liver transplant setting.
@ast
Drug-drug interactions with or ...... the liver transplant setting.
@en
type
label
Drug-drug interactions with or ...... the liver transplant setting.
@ast
Drug-drug interactions with or ...... the liver transplant setting.
@en
prefLabel
Drug-drug interactions with or ...... the liver transplant setting.
@ast
Drug-drug interactions with or ...... the liver transplant setting.
@en
P2860
P1476
Drug-drug interactions with or ...... the liver transplant setting.
@en
P2093
Robert J Fontana
Sarah Tischer
P2860
P304
P356
10.1016/J.JHEP.2013.11.013
P577
2013-11-23T00:00:00Z